<?xml version="1.0" encoding="UTF-8"?>
<results title="drugs">
 <result pre="receptors, 5-HT2A and 5-HT2C receptors and others. Notable examples include" exact="oseltamivir" post="which may act as MAO inhibitor and efavirenz, which"/>
 <result pre="which may be similar to those of the psychedelic hallucinogen" exact="lysergic acid diethylamide" post="(LSD). Other antiviral drugs with prominent nervous system effects"/>
 <result pre="they occur and manage them appropriately. central nervous system antiviral" exact="efavirenz" post="peripheral neuropathy monoamine oxidase The content published in Cureus"/>
 <result pre="individual agents, were searched separately using multiple search strings (e.g.," exact="ribavirin" post="AND neurotoxicity, efavirenz psychiatric effects, efavirenz AND psychosis, acyclovir"/>
 <result pre="searched separately using multiple search strings (e.g., ribavirin AND neurotoxicity," exact="efavirenz" post="psychiatric effects, efavirenz AND psychosis, acyclovir AND nervous system)."/>
 <result pre="multiple search strings (e.g., ribavirin AND neurotoxicity, efavirenz psychiatric effects," exact="efavirenz" post="AND psychosis, acyclovir AND nervous system). The search retrieved"/>
 <result pre="authors. Neuropsychiatric effects of antiviral therapy in influenza Oseltamivir and" exact="zanamivir" post="are neuraminidase inhibitors, used for treating influenza by shortening"/>
 <result pre="in the USA, Spain, Japan, China and South Korea associate" exact="oseltamivir" post="with many neuropsychiatric adverse events and abnormal behaviors such"/>
 <result pre="for conversion to the active form of the neuraminidase inhibitor" exact="oseltamivir" post="carboxylate (OC). Oseltamivir inhibits human monoamine oxidase‐A (MAO‐A), which"/>
 <result pre="to be other candidates for investigation. Another study reported that" exact="oseltamivir" post="sialylates a serum glycolipid that stimulates D2 dopaminergic receptor."/>
 <result pre="to abnormal behavior reported in some children taking oseltamivir. Unchanged" exact="oseltamivir" post="phosphate is suggested to be related to central nervous"/>
 <result pre="Health, Labour and Welfare (MHLW) warned against the use of" exact="oseltamivir" post="in children aged 10-19 years because of the possible"/>
 <result pre="Food and Drug Administration (FDA) added a warning to the" exact="oseltamivir" post="label in 2006 to draw attention to the risk"/>
 <result pre="of neuropsychiatric adverse events (NPAEs). However, a causal association between" exact="oseltamivir" post="use and abnormal behaviors or sudden death has not"/>
 <result pre="is no evidence, nor plausible mechanism of action, to link" exact="oseltamivir" post="with neuropsychiatric adverse events. They concluded that the risk"/>
 <result pre="of abnormal behavior was increased by influenza, and not by" exact="oseltamivir" post="use [4]. As far as the use of zanamivir"/>
 <result pre="by oseltamivir use [4]. As far as the use of" exact="zanamivir" post="is concerned, no major neuropsychiatric adverse events have been"/>
 <result pre="of antiviral therapy in herpes and cytomegalovirus (CMV) Aciclovir, valacyclovir," exact="famciclovir" post="are medications used for the treatment of herpes infections."/>
 <result pre="days of administration. Cessation of the gancyclovir and administration of" exact="haloperidol" post="resulted in recovery. Most patients with psychosis due to"/>
 <result pre="for the treatment of hepatitis B include lamivudine, telbivudine, and" exact="entecavir" post="(classified as nucleoside analogues), and the nucleotide analogues adefovir"/>
 <result pre="(classified as nucleoside analogues), and the nucleotide analogues adefovir dipivoxil," exact="tenofovir" post="disoproxil fumarate and tenofovir alafenamide [10]. Lamivudine and telbivudine"/>
 <result pre="and the nucleotide analogues adefovir dipivoxil, tenofovir disoproxil fumarate and" exact="tenofovir" post="alafenamide [10]. Lamivudine and telbivudine have been associated with"/>
 <result pre="dipivoxil, tenofovir disoproxil fumarate and tenofovir alafenamide [10]. Lamivudine and" exact="telbivudine" post="have been associated with myopathy and peripheral neuropathy, with"/>
 <result pre="mitochondrial DNA [11]. An interesting report of two cases of" exact="lamivudine" post="induced dystonia has been reported, which responded to prompt"/>
 <result pre="prompt administration of anticholinergic agents and did not recur after" exact="lamivudine" post="discontinuation [12]. The clinical presentation was similar to the"/>
 <result pre="dystonic reactions associated with antipsychotic drugs, which are mediated by" exact="dopamine" post="D2 receptor antagonism in the striatum. At present, there"/>
 <result pre="in the striatum. At present, there is no evidence that" exact="lamivudine" post="interacts with dopamine receptors, so this could be regarded"/>
 <result pre="At present, there is no evidence that lamivudine interacts with" exact="dopamine" post="receptors, so this could be regarded as an extremely"/>
 <result pre="idiosyncratic reaction. In another study, three of six patients with" exact="lamivudine" post="or telbivudine­associated myopathy had a complaint of numbness in"/>
 <result pre="by the study team. Out of 3,500 patients who received" exact="telbivudine" post="monotherapy in clinical trials, 10 (0.28%) were reported to"/>
 <result pre="combination therapy of pegylated interferon and telbivudine. Moreover, patients receiving" exact="telbivudine" post="treatment, suffer from weakness in upper and lower extremities"/>
 <result pre="were reported as the most frequent adverse events associated with" exact="telbivudine" post="use. Entecavir is a highly selective guanosine nucleoside analogue,"/>
 <result pre="(10%­-13%), and dizziness (9%), while 1-10% of patients treated with" exact="entecavir" post="suffer from insomnia. Entecavir­-associated myopathy and peripheral neuropathy cases"/>
 <result pre="cases were very rarely reported in the literature. Patients receiving" exact="entecavir" post="presenting with severe lactic acidosis, complain of weakness, reduced"/>
 <result pre="and potentially serious consequences. The combination of pegylated interferon and" exact="ribavirin" post="was the mainstay of treatment for hepatitis C infection"/>
 <result pre="loss of motivation, and depressed mood [13]. The use of" exact="ribavirin" post="in combination with either interferon or direct-acting antivirals may"/>
 <result pre="side effects of treatment with the combination of interferon and" exact="ribavirin" post="[13]. However, clinically signiﬁcant neurological toxicity is reported in"/>
 <result pre="rates of insomnia and fatigue as compared with rates from" exact="boceprevir" post="and telaprevir and suggested that these new agents may"/>
 <result pre="insomnia and fatigue as compared with rates from boceprevir and" exact="telaprevir" post="and suggested that these new agents may be better"/>
 <result pre="depression (1%) have been reported in relation to treatment with" exact="sofosbuvir" post="and may suggest mild neurotoxicity [21]. In patients receiving"/>
 <result pre="At the end of a course of treatment with a" exact="sofosbuvir" post="(SOF)-based regimen, patients with cirrhosis exhibited an increase in"/>
 <result pre="profile, though the strength of the association varies. Didanosine and" exact="stavudine" post="have been more strongly associated with peripheral neuropathy, whereas"/>
 <result pre="stavudine have been more strongly associated with peripheral neuropathy, whereas" exact="zidovudine" post="has more commonly been associated with myopathy and myelotoxicity."/>
 <result pre="more commonly been associated with myopathy and myelotoxicity. The pro-drug" exact="tenofovir" post="alafenamide, which leads to greater concentrations of the active"/>
 <result pre="cells, may be better tolerated than the initial formulation of" exact="tenofovir" post="disiproxil fumarate as well as most other NRTIs, though"/>
 <result pre="effect seems to be reversible, with gradual symptom improvement following" exact="zidovudine" post="discontinuation [28]. In contemporary clinical settings, the incidence of"/>
 <result pre="the incidence of peripheral neuropathy or myopathy during treatment with" exact="zidovudine" post="could be managed by drug discontinuation, given the availability"/>
 <result pre="compared to other NRTIs. Peripheral neuropathy is less common with" exact="tenofovir" post="compared to other NRTIs (especially stavudine), although it does"/>
 <result pre="A report of nine cases of neuropsychiatric complications arising following" exact="tenofovir" post="initiation in individuals on efavirenz containing regimen suggests the"/>
 <result pre="of neuropsychiatric complications arising following tenofovir initiation in individuals on" exact="efavirenz" post="containing regimen suggests the need for further monitoring and"/>
 <result pre="be reduced by the use of the more selective pro-drug" exact="tenofovir" post="alafenamide, though further research is warranted to determine whether"/>
 <result pre="inhibitors, and it is available in a fixed-dose combination with" exact="emtricitabine" post="and tenofovir, but tablets containing only efavirenz (to be"/>
 <result pre="fixed-dose combination with emtricitabine and tenofovir, but tablets containing only" exact="efavirenz" post="(to be used in combinations with other antiretroviral drugs)"/>
 <result pre="developed a few weeks after treatment initiation [35]. Abuse of" exact="efavirenz" post="has also been reported, primarily in South Africa where"/>
 <result pre="been reported, primarily in South Africa where crushed tablets of" exact="efavirenz" post="were smoked in a combination of drugs (including marijuana"/>
 <result pre="Recent evidence from in vitro and animal studies indicate that" exact="efavirenz" post="is a potent psychotropic drug with significant affinity GABA-A"/>
 <result pre="studies of efavirenz, are far more likely to occur with" exact="efavirenz" post="compared with other antiretroviral drugs and limit regimen tolerability"/>
 <result pre="case reports [38] of psychotic symptomatology and mania attributed to" exact="nevirapine" post="have been published, but such events have been exceedingly"/>
 <result pre="agent of this class to be approved in 1995 with" exact="ritonavir" post="following in 1996. Protease inhibitors may be used as"/>
 <result pre="As a class, they are notorious for pharmacokinetic interactions as" exact="ritonavir" post="is a potent inhibitor of CYP3A4, potentiating the effect"/>
 <result pre="of cerebral small vessel disease via this mechanism. Abuse of" exact="ritonavir" post="has also been reported, especially in combination with other"/>
 <result pre="drug of this class to be approved in 2007, with" exact="elvitegravir" post="and dolutegravir being approved in 2012 and 2013, respectively."/>
 <result pre="this class to be approved in 2007, with elvitegravir and" exact="dolutegravir" post="being approved in 2012 and 2013, respectively. They inhibit"/>
 <result pre="efavirenz. Integrase inhibitor-containing regimens are, however, far less likely than" exact="efavirenz" post="containing HAART regimens to be associated with neuropsychiatric side"/>
 <result pre="may contribute to decreased treatment adherence [48]. The association between" exact="dolutegravir" post="and psychiatric adverse events is stronger than for the"/>
 <result pre="and Fusion Inhibitors Among the most recently approved antiretrovirals are" exact="maraviroc" post="and enfuvirtide, two agents belonging to this class. They"/>
 <result pre="not been associated with treatment-limiting neuropsychiatric adverse effects. Substitution of" exact="efavirenz" post="with one of these drugs may reduce the risk"/>
 <result pre="clearly outweigh risk. Relevant only for oseltamivir. Antiehrpetic drugs (acyclovir," exact="ganciclovir" post="and analogs) Hallucinations, confusion, acute psychosis with acute onset"/>
 <result pre="antivirals – not clear whether side effects are attributable to" exact="ribavirin" post="alone. Direct-acting antiviral agents for hepatitis C Depression, insomnia,"/>
 <result pre="more prone to causing NPAE compared to sofosbuvir-based regimens. Concurrent" exact="ribavirin" post="use may exacerbated NPAEs. Nucleoside / Nucleotide analogues Peripheral"/>
 <result pre="most pronounced upon initiation of treatment 5-HT2A antagonism, serotonin and" exact="dopamine" post="reuptake inhibition, MAO inhibition, GABA-A receptor modulation NPAEs are"/>
 <result pre="association with NPAEs Unknown May be used in place of" exact="efavirenz" post="if it not tolerated due to NPAEs. Conclusions Neuropsychiatric"/>
 <result pre="in an adult patient with influenza a (H3N2) treated with" exact="oseltamivir" post="(Tamiflu): a case reportBMC Infect DisChenRFangZHuangY22419201930832611 2Risk of neuropsychiatric"/>
 <result pre="ScandHamaRBennettCL148160135201727364959 4Analysis of neuropsychiatric adverse events in patients treated with" exact="oseltamivir" post="in spontaneous adverse event reportsBiol Pharm BullUedaNUmetsuRAbeJet al.1638164438201526424023 5The"/>
 <result pre="oseltamivir in spontaneous adverse event reportsBiol Pharm BullUedaNUmetsuRAbeJet al.1638164438201526424023 5The" exact="aciclovir" post="metabolite CMMG is detectable in the CSF of subjects"/>
 <result pre="detectable in the CSF of subjects with neuropsychiatric symptoms during" exact="aciclovir" post="and valaciclovir treatmentJ Antimicrob ChemotherHelldenALyckeJVanderTSvenssonJ-OOdar-CederlofIStahleL94594957200616540518 6Neuropsychiatric manifestations in a"/>
 <result pre="the CSF of subjects with neuropsychiatric symptoms during aciclovir and" exact="valaciclovir" post="treatmentJ Antimicrob ChemotherHelldenALyckeJVanderTSvenssonJ-OOdar-CederlofIStahleL94594957200616540518 6Neuropsychiatric manifestations in a patient undergoing"/>
 <result pre="by lamivudineClin NeuropharmacolSongXHuZZhangH19319428200516062101 13Psychiatric side effects of pegylated interferon-alpha and" exact="ribavirin" post="therapy in Iranian patients with chronic hepatitis C: a"/>
 <result pre="14A case report of psychiatric symptoms following direct-acting antiviral and" exact="ribavirin" post="combination therapy for chronic hepatitis C in a patient"/>
 <result pre="studyBMJ Open GastroenterolVolpatoSMontagneseSZanettoAet al.042017 18Patient characteristics, safety, and tolerability with" exact="telaprevir" post="treatment for HCV in the clinic: a retrospective, multicenter"/>
 <result pre="retrospective, multicenter studyJ Clin Transl HepatolFlammSLPockrosPJBengtssonLFriedmanM65732201426356545 19Overall safety profile of" exact="boceprevir" post="plus peginterferon alfa-2b and ribavirin in patients with chronic"/>
 <result pre="studyJ Clin Transl HepatolFlammSLPockrosPJBengtssonLFriedmanM65732201426356545 19Overall safety profile of boceprevir plus" exact="peginterferon alfa-2b" post="and ribavirin in patients with chronic hepatitis C genotype"/>
 <result pre="HepatolFlammSLPockrosPJBengtssonLFriedmanM65732201426356545 19Overall safety profile of boceprevir plus peginterferon alfa-2b and" exact="ribavirin" post="in patients with chronic hepatitis C genotype 1: a"/>
 <result pre="31Neuropsychiatric adverse events after switching from an antiretroviral regimen containing" exact="efavirenz" post="without tenofovir to an efavirenz regimen containing tenofovir: a"/>
 <result pre="events after switching from an antiretroviral regimen containing efavirenz without" exact="tenofovir" post="to an efavirenz regimen containing tenofovir: a report of"/>
 <result pre="from an antiretroviral regimen containing efavirenz without tenofovir to an" exact="efavirenz" post="regimen containing tenofovir: a report of nine casesAntivir TherAllavenaCLe"/>
 <result pre="report of nine casesAntivir TherAllavenaCLe MoalGMichauCChiffoleauARaffiF263265112006https://www.researchgate.net/profile/Anne_Chiffoleau/publication/7141177_Neuropsychiatric_adverse_events_after_switching_from_an_antiretroviral_regimen_containing_efavirenz_without_tenofovir_to_an_efavirenz_regimen_containing_tenofovir_A_report_of_nine_cases/links/0c96053bf9003dddbe000000.pdf16640107 32Efficacy and safety of" exact="tenofovir" post="alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations"/>
 <result pre="casesAntivir TherAllavenaCLe MoalGMichauCChiffoleauARaffiF263265112006https://www.researchgate.net/profile/Anne_Chiffoleau/publication/7141177_Neuropsychiatric_adverse_events_after_switching_from_an_antiretroviral_regimen_containing_efavirenz_without_tenofovir_to_an_efavirenz_regimen_containing_tenofovir_A_report_of_nine_cases/links/0c96053bf9003dddbe000000.pdf16640107 32Efficacy and safety of tenofovir alafenamide versus" exact="tenofovir" post="disoproxil fumarate given as fixed-dose combinations containing emtricitabine as"/>
 <result pre="alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing" exact="emtricitabine" post="as backbones for treatment of HIV-1 infection in virologically"/>
 <result pre="review of the psychiatric side-effects of efavirenzAIDS BehavKenediCAGoforthHW1803181815201121484283 34Impact of" exact="efavirenz" post="on neuropsychological performance and symptoms in HIV-infected individualsAnn Intern"/>
 <result pre="medication in South AfricaAIDS BehavGrelottiDJClossonEFSmitJAet al.51151818201423955659 37The HIV antiretroviral drug" exact="efavirenz" post="has LSD-like propertiesNeuropsychopharmacologyGatchMBKozlenkovAHuangR-Qet al.2373238438201323702798 38Drug points: Neuropsychiatric complications of"/>
 <result pre="efavirenz has LSD-like propertiesNeuropsychopharmacologyGatchMBKozlenkovAHuangR-Qet al.2373238438201323702798 38Drug points: Neuropsychiatric complications of" exact="nevirapine" post="treatmentBMJWiseMEJMistryKReidS879324200211950737 39Stavudine- and nevirapine-related drug toxicity while on generic"/>
 <result pre="protease inhibitor-containing therapyClin Infect DisDuvalXJournotVLeportCet al.24825539200415307035 44Neuropsychiatric adverse events with" exact="dolutegravir" post="and other integrase strand transfer inhibitorsAIDS RevHoffmannCLlibreJM41021201930899113 45Neurological response"/>
 <result pre="infectionAIDSCohenCElionRRuanePet al.712252011 48Higher rates of neuropsychiatric adverse events leading to" exact="dolutegravir" post="discontinuation in women and older patientsHIV MedHoffmannCWelzTSabranskiMet al.566318201727860104 49Comparison"/>
 <result pre="switchingInfect ChemotherKimMJKimS-WChangH-Het al.23123847201526788406 50Safety, efficacy and indications of prescription of" exact="maraviroc" post="in clinical practice: Factors associated with clinical outcomesAntiviral ResLlibreJMRiveroARojasJFet"/>
</results>
